chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Introduction

  • Also known as chronic myelogenous, myelocytic, or chronic granulocytic leukemia
  • Has three phases: chronic, accelerated & blast
  • Median age at presentation is at >50 years old

Definition

  • A myeloid disorder associated with Philadelphia (Ph) chromosome t(9;22)(q34;q11), a fusion of the breakpoint cluster region (BCR) & Abelson murine leukemia (ABL1) genes

Signs and Symptoms

  • Systemic symptoms:
    • Anemia
    • Abdominal fullness
    • Abdominal pain that may present with left upper quadrant pain & early satiety
    • Bleeding episodes due to platelet dysfunction
    • Fatigue
    • Malaise
    • Weight loss
  • Other frequent findings:
    • Splenomegaly
    • Platelet count raised
    • White blood cell (WBC) count increased
    • Involvement of lymph nodes, skin & soft tissue (patients with blast crisis)

Risk Factors

  • The only known risk factor is exposure to ionizing radiation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Feb 2018

Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.